Balaxi Pharmaceuticals Ltd
Ticker: BALAXI
Decent
63/100
☆ Add to Watchlist
Investing Reference
Price
42.94
Market Cap
237.06
Debt/Equity
0.2306
ROE %
11.577
PB
1.0230
Promoter %
65.991
Pledge %
0.000
1Y Rev Growth %
21.908
5Y Rev Growth %
44.869
NP Margin %
8.501
NP Margin 5Y Avg %
10.830
Trading Reference
1M Return %
-4.558
6M Return %
-21.398
1Y Return %
-52.262
% Away 52W High
116.139
% Away 52W Low
5.348
Daily Volume
38959
Investment Verdict
Buy
Score 84/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 22/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Balaxi Pharmaceuticals Ltd shows potential for growth amid strong market demand.
✅ Positives
- Strong revenue growth in recent quarters
- Expanding product portfolio and R&D investments
- Favorable regulatory environment for pharmaceuticals
⚠️ Negatives
- High competition in the pharmaceutical sector
- Rising raw material costs impacting margins
- Dependence on a few key products for revenue
Verdict
Moderate growth potential with some risks.
Recommendation: Consider buying on dips.
Upside Probability: 25% | Downside Probability: 15%
Last generated: 30/10/2025
More Options
U
U. Y. Fincorp Ltd
U. Y. Fincorp Ltd is facing several challenges, including inconsistent growth and profitability metrics, which make it a risky investment at this time.
View details
S
Sugs Lloyd Ltd
Sugs Lloyd Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
B
Bimetal Bearings Ltd
Bimetal Bearings Ltd shows decent potential but faces challenges in profitability and valuation metrics. Investors should be cautious.
View details
P
Precision Electronics Ltd
Precision Electronics Ltd shows potential but faces several challenges that could impact future performance. Investors should proceed with caution.
View details
C
Chemkart India Ltd
Chemkart India Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
V
Vaarad Ventures Ltd
Vaarad Ventures Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
D
Delphi World Money Ltd
Delphi World Money Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
Competent Automobiles Company Ltd
Competent Automobiles Company Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
K
KCK Industries Ltd
KCK Industries Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Shivalic Power Control Ltd
Shivalic Power Control Ltd presents a risky investment opportunity with several concerns in growth consistency and market sentiment.
View details
P
Positron Energy Ltd
Positron Energy Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
C
Chembond Material Technologies Ltd
Chembond Material Technologies Ltd shows potential for growth and stability, but investors should be cautious of execution risks and governance concerns.
View details
K
Kapston Services Ltd
Kapston Services Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
G
GLEN Industries Ltd
GLEN Industries Ltd shows potential but faces challenges in growth consistency and valuation metrics.
View details
T
Trishakti Industries Ltd
Trishakti Industries Ltd presents a risky investment opportunity due to inconsistent growth and profitability metrics, alongside concerns in governance and market sentiment.
View details
S
Spectrum Talent Management Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Balaxi Pharmaceuticals Ltd is a leading player in the Indian pharmaceutical industry, dedicated to improving healthcare through innovative solutions. Catering to a diverse range of medical needs, Balaxi focuses on developing high-quality generic medications and specialty drugs. With a commitment to research and development, the company plays a crucial role in making healthcare accessible and affordable for all. Balaxi's strong distribution network ensures that its products reach patients in need across the country.
- Established leader in the Indian pharma sector
- Focus on affordable and high-quality medications
- Strong commitment to research and innovation
- Wide range of therapeutic areas covered
- Robust distribution network across India
Investment Thesis
Balaxi Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company for long-term success in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services portfolio offers substantial growth runway.
- Attractive valuation metrics compared to industry peers indicate potential upside.
- Robust financial performance signals resilience in a competitive market.
- Strategic focus on innovation aligns with evolving healthcare demands.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Strong pipeline of new drugs
- Expansion into international markets
- Strategic partnerships with hospitals
- Increasing focus on R&D
Risks ⚠️
- Regulatory hurdles in drug approvals
- Intense competition in pharmaceuticals
- Dependence on key patents
- Market volatility affecting stock price
- Potential supply chain disruptions
Peer Perspective
Balaxi Pharmaceuticals Ltd trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin volatility. A stable margin improvement could trigger a rerating, aligning it closer to its competitors.
Future Outlook
Balaxi Pharmaceuticals Ltd is well-positioned for growth, driven by its innovative pipeline and expanding market presence. Successful execution of its strategic initiatives and effective cost control will be crucial for maximizing shareholder value.
AI FAQs for Retail Users
- Q: What does Balaxi Pharmaceuticals Ltd do?A: Balaxi Pharmaceuticals Ltd specializes in developing and manufacturing pharmaceutical products for various therapeutic areas.
- Q: Is Balaxi Pharmaceuticals Ltd listed on Indian stock exchanges?A: Yes, Balaxi Pharmaceuticals Ltd is listed on major Indian stock exchanges, including NSE and BSE.
- Q: What factors influence Balaxi Pharmaceuticals Ltd's stock price?A: Stock price can be influenced by company performance, market trends, regulatory changes, and overall economic conditions.
- Q: How can I invest in Balaxi Pharmaceuticals Ltd?A: You can invest through a brokerage account by purchasing shares on the stock exchange.
- Q: What are the risks of investing in Balaxi Pharmaceuticals Ltd?A: Risks include market volatility, regulatory challenges, and competition within the pharmaceutical industry.
📊 Stock Investment Checklist (100 Points)
Balaxi Pharmaceuticals Ltd • Updated: 2025-09-17 01:30:22
-
10BusinessHighPharmaceuticals is a growing sector with increasing demand.
-
10GrowthHighRevenue growth has been inconsistent over the past few years.
-
8ProfitabilityHighROE and ROCE are below industry averages.
-
10ValuationHighP/E ratio is higher than peers, indicating potential overvaluation.
-
6BalanceGoodDebt levels are manageable, but liquidity is a concern.
-
7GovernanceHighPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth catalysts identified.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 63 / 100
• Decent
Balaxi Pharmaceuticals has potential but faces significant challenges in growth and profitability metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 70/100